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The three reviews that follow this introduction reflect con- 
temporary knowledge of human immunodeficiency virus 
(HIV) infection and disease induction. Let us take a step 
back and reflect on why this virus infection, against which 
10% of the budget of the National Institutes of Health is 
deployed, remains so enigmatic. 
The key fact about HIV is that it is a nonequilibrium 
infectious organism. This contrasts with agents that exist 
at equilibrium with the human population. Poliovirus, for 
instance, achieved an equilibrium relationship with hu- 
mans and has no contemporary animal reservoir, although 
it must have evolved from a virus infecting a lower animal. 
As a solely human pathogen, it coexisted with its human 
host in a stable relationship until vaccination tipped the 
balance against the virus. Smallpox or measles viruses 
are other such examples. 
A nonequilibrium human virus is one that presumably 
has a stable equilibrium with another species (or it would 
not exist) but infects humans occasionally. It may then 
spread in humans or not, but if it spreads, it will be in 
constant genetic flux until it either peters out or evolves 
a stable situation. Not being evolved to coexist with hu- 
mans, it can be strikingly lethal to us--as Ebola periodi- 
cally illustrates--or can induce strange pathologies, like 
HIV. An underappreciated example is influenza virus, 
which maintains an equilibrium relationship with birds and 
periodically enters the human population causing remark- 
ably severe symptoms and even lethal pandemics. Basi- 
cally, each nonequilibrium infection poses its own particu- 
lar series of idiosyncrasies because the host and virus 
have not evolved to a predictably stable relationship. 
There is little doubt that HIV-2 is derived from a monkey 
virus that often infects humans, particularly in West Africa. 
HIV-1 was presumably transferred from an African primate 
to humans in the recent past, but is entirely maintained 
today by human-to-human passage. As it moves through 
the human population, it shows the nonequilibrium behav- 
ior of constant mutation and selection. Whether it will settle 
down to a more stable relationship remains to be seen. It 
also produces a remarkably high rate of mortality following 
a unique course of events. Because studies of viral pathol- 
ogy in humans are so difficult and because HIV does not 
cause its characteristic pathology in any other species, 
our understanding of the unique pathological process 
caused by HIV has been slow to develop and remains 
spotty. 
Given the difficulty of the work, there has been impres- 
sive progress in illuminating the pathogenic process. 
Many investigators now believe that although HIV infection 
shows three phases-- acute, chronic but clinically inappar- 
ent, and overtly deteriorating--these r flect three different 
aspects of the host response to an unvarying challenge 
of a virus that passes continually among CD4-positive 
cells. In the acute stage, the host has yet to mount an 
immune response. That response is now thought to be 
dominated by cytotoxic T lymphocytes (CTLs) that can kill 
HIV-infected cells. The role of the antibody response, if it 
is at all effective, remains uncertain. Once the CTL re- 
sponse is effective, the circulating virus rapidly falls to a 
lower level, the particular set point varying widely from 
person to person. That level may be the determinant of 
the length of the ensuing inapparent phase, which is also 
very variable. In all but a few infected people, the immune 
system finally breaks down under the onslaught of the 
virus, and secondary infections, cancer, and nervous sys- 
tem deterioration lead to death. 
An interesting aspect of present-day research on HIV 
infection is the concentration on the few infected people 
who are an exception to the general behavior of the infec- 
tion. Some are long-term survivors, including a few who 
show no progression of their disease after 10 or 15 years 
of being infected. The hope is that their situation will give 
a clue how to stop the progression of disease in the others. 
Another odd population is people who have been inten- 
sively exposed to HIV but remain apparently uninfected. 
William Paul in his review concentrates on these and other 
clues suggesting that the immune system can control the 
virus and that therefore a vaccine should be possible. It 
is an optimistic scenario, but it does not consider the possi- 
bility that the lesson may be in the majority of cases in 
which the immune response is ultimately ineffective. We 
will see which model is most informative. 
A range of evidence suggests that HIV can establish 
a nonproductive relationship with infected cells. Joseph 
"Mike" McCune discusses what role such virus-cell rela- 
tionships might have to the evolution of the infectious pro- 
cess. This is a timely discussion because the preponder- 
ance of recent evidence has focused on the maintenance 
of the infection by continual cell-to-cell passage and the 
role of latency has been minimized. What is certain is that 
the last word is not in and that we must keep an open 
mind about what events occur in the infected person that 
allow this unique infection to be so devastating. 
HIV has a unique genetic makeup including a series of 
small genes that make powerful, multifunctional proteins. 
Didier Trono discusses a subset of these, called "acces- 
sory genes" because their deletion is not deleterious to 
growth of HIV in certain cell cultures. Their activity is 
thought o drive some of the singular pathology of HIV, but 
the connection remains elusive. The recent demonstration 
that simian immunodeficiency virus can cause AIDS-like 
symptoms in neonatal monkeys, even in the absence of 
accessory genes that are critical to the pathogenesis in 
adult animals, underscores our lack of understanding of 
the importance of these genes. For the molecular biologist, 
the small genes of HIV and other lentiviruses continue to 
pose especially intriguing puzzles because none of them 
act in ways that yet fit comfortably within today's para- 
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digms and yet they are involved in the central processes 
of gene regulation, RNA processing, cellular signaling, or 
cell cycle regulation. 
The HIV research field continues its glacial forward 
movement, some fronts of which are covered here. The 
front that matters most is the development of vaccines or 
effective therapies. There has been little recent progress 
on the vaccine side, although the developing evidence of 
the effectiveness of the human T cell-mediated immune 
response offers renewed hope. New drugs are undergoing 
tests, especially protease inhibitors, and are highly effec- 
tive until the mutability of the virus allows it to find a way 
around them. There is tempered optimism that combined 
drug therapy may make a dent in the problem. Gene ther- 
apy is still a dream, although not a fantasy. Increased basic 
understanding of the virus and the pathogenic process it 
induces can give clues that might lead to novel protective 
and therapeutic interventions and is still desperately needed. 
